Pharmaceutical giant Merck has struck a drug discovery partnership with Protillion, a company using artificial intelligence to accelerate the hunt for new medicines, according to Genetic Engineering and Biotechnology News. The collaboration carries potential milestone payments of up to $510 million.
The $510 million figure is a ceiling, not a guaranteed payout. In pharma deals, "milestone payments" are tranches of money released only when specific research or development targets are hit — for example, when a drug candidate advances from lab testing into human trials, or achieves regulatory approval. This structure means Protillion earns more as it delivers results, while Merck limits its upfront financial exposure.
The deal reflects a broader trend reshaping the pharmaceutical industry: large drugmakers are increasingly turning to AI-native startups to speed up the notoriously slow and expensive process of identifying and validating new drug candidates. Traditional drug discovery can take years of trial and error; AI systems can rapidly sift through vast biological datasets to surface promising compounds or predict how molecules will behave in the body.
For Merck, the collaboration adds another AI-powered tool to its pipeline without requiring it to build the underlying technology in-house. For Protillion, a deal with a global pharma leader provides both funding and a validation of its platform.
If AI-assisted discovery can reliably compress timelines and cut failure rates, it could fundamentally change how — and how quickly — new treatments reach patients.